Altimmune ALT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $41K+105% | $20K0.0% | $20K0.0% | $20K0.0% | ||
| $66.8M+0.5% | $66.43M-2.0% | $67.8M-6.7% | $72.65M-5.1% | $76.57M-6.9% | ||
| $30.16M+7.3% | $28.1M+23.9% | $22.68M+4.3% | $21.74M+0.4% | $21.65M+3.2% | ||
| $96.95M+2.6% | $94.53M+4.5% | $90.48M-4.1% | $94.39M-3.9% | $98.21M-4.8% | ||
| -$96.92M-2.6% | -$94.49M-4.5% | -$90.46M+4.1% | -$94.37M+3.9% | -$98.19M+4.8% | ||
| $2.7M+65.2% | $1.64M+115% | $761K+180% | $272K+2,922% | $9K0.0% | ||
| $5.84M+2.1% | $5.72M-2.6% | $5.87M-1.3% | $5.94M-18.3% | $7.27M-10.4% | ||
| -$91.08M-2.6% | -$88.77M-4.9% | -$84.6M+4.3% | -$88.43M+2.7% | -$90.92M+4.4% | ||
| —— | —— | —— | —— | —— | ||
| -$91.08M-3.4% | -$88.09M-5.0% | -$83.92M+4.4% | -$87.75M+2.8% | -$90.24M+5.1% | ||
| -$0.92+8.0% | -$1.00+6.5% | -$1.07+9.3% | -$1.18+6.3% | -$1.26+6.0% | ||
| -$96.81M-2.6% | -$94.38M-4.5% | -$90.34M+4.1% | -$94.24M+3.9% | -$98.03M+4.8% | ||
| -$96.92M-2.6% | -$94.49M-4.5% | -$90.46M+4.1% | -$94.37M+3.9% | -$98.19M+4.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Altimmune's revenue?
- Altimmune (ALT) generated $41.0K in revenue over the trailing twelve months, up 105.0% year over year.
- Is Altimmune profitable?
- Altimmune is not currently profitable: it reported a net loss of $91.1M over the trailing twelve months, a -214861.0% net margin.
- What is Altimmune's earnings per share?
- Altimmune's diluted EPS over the trailing twelve months is $-0.92.
- Where does Altimmune's income statement data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
